TP53 and acute lymphoblastic leukemia: In the research field, these technologies have allowed for genomic characterization even at the single-cells level to identify driver mutations related to disease development in high-risk subtypes such as KMT2Ar [168,169], or genetic alterations relevant to disease progression and treatment response in genes such as TTN, FLT3, TP53, MUC16, and EPPK1 in B-ALL, and NOTCH1, FBXW7, TTN, MUC16, and PHF6 in T-ALL [170].